Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 15/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18059054 | 0.81 | ALDH1A1 (0.32) | — | |
| SCHEMBL18059095 | 0.74 | SLC6A2 (0.34) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL12023797 | 0.74 | SLC6A2 (0.37) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL63229 | 0.71 | MEN1 (0.34) | SLC6A2SLC6A4 | |
| SCHEMBL12321361 | 0.71 | IDO1 (0.42) | SLC6A3SLC6A2SLC6A4IDO1TDO2 | |
| SCHEMBL4481321 | 0.62 | TSHR (0.50) | IDO1TDO2 | |
| SCHEMBL13879701 | 0.62 | MAOA (0.41) | SLC6A3SLC6A2SLC6A4IDO1 | |
| SCHEMBL25399431 | 0.61 | LMNA (0.40) | — | |
| SCHEMBL17684783 | 0.61 | SLC6A2 (0.57) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL4959033 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802936-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802936-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-9802936-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| EP-2392561-B1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2392561-B1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-1534658-B1 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2016-09-07 | — | — | EP | disclosed |
| US-8129355-B2 | Nuclear receptor-based inducible gene expression system; modulating the expression of a gene in a host cell by introducing into the host cell a gene expression modulation system and activating that system using 5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid (1-benzoyl-cyclopentyl)-amide | INTREXON CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129355-B2 | Nuclear receptor-based inducible gene expression system; modulating the expression of a gene in a host cell by introducing into the host cell a gene expression modulation system and activating that system using 5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid (1-benzoyl-cyclopentyl)-amide | INTREXON CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129355-B2 | Nuclear receptor-based inducible gene expression system; modulating the expression of a gene in a host cell by introducing into the host cell a gene expression modulation system and activating that system using 5-ethyl-2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid (1-benzoyl-cyclopentyl)-amide | INTREXON CORPORATION (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2392561-A1 | Alpha-acylaminoketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | Intrexon Corporation (US) | 2011-12-07 | — | — | EP | disclosed |
| US-20080125465-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125465-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125465-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-29 | — | — | US | disclosed |
| US-7375093-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375093-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375093-B2 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1534658-A4 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE INC (US) | 2006-10-04 | — | — | EP | disclosed |
| EP-1534658-A2 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040049037-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2004005478-A2 | KETONE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040049037-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | ESRRB, ESRRA, KDELR1 | SLC6A3 3367/4885SLC6A2 4087/4885SLC6A4 4096/4885 |
| US-20080125465-A1 | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | ESRRB, ESRRA, KDELR1 | SLC6A3 3367/4885SLC6A2 4087/4885SLC6A4 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.